Login to Your Account



Roche Takeover In The Works?

Trimeris Reduces Work Force, Programs To Boost Earnings

By Randall Osborne


Thursday, November 16, 2006
Trimeris Inc.'s plan to shift emphasis for a tighter focus on its marketed HIV drug, Fuzeon, boosted speculation that the company is grooming for a potential acquisition, the likes of which the industry has seen several lately. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription